ArticleNeoplasia (New York, N.Y.)2022
Microbial mechanisms to improve immune checkpoint blockade responsiveness.
Article in Neoplasia (New York, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- Select intratumoral riboflavin-auxotrophicProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Metagenomic and Metabolomic Correlates of Immunotherapy Response in Non-Small Cell Lung Cancer.Research square · 2026Article
- Can Complex 3D Models Effectively Replace 2D and Animal Models to Investigate the Microbe-Tumor-Immune Axis in Pancreatic Cancer Studies?Nutrients · 2026Review
- Immune-microbiota crosstalk in colorectal cancer: mechanistic pathways, biomarkers, and translational therapeutics.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Influence of Gut Microbiota on Response to Immune Check Point Inhibitors in MASLD Patients With HCC: Unraveling the Connection.Cancer medicine · 2026Review
- Gut-Liver Microbiome and Tumor Microenvironment in Metabolic Dysfunction-Associated Steatotic Liver Disease.Advances in experimental medicine and biology · 2026Review
- Lactobacilli-Derived Microbe-Associated Molecular Patterns (MAMPs) in Host Immune Modulation.Biomolecules · 2025Review
- Gut Microbiota and Ferroptosis in Colorectal Cancer: A Comprehensive Review of Mechanisms and Therapeutic Strategies to Overcome Immune Checkpoint Resistance.Biomolecules · 2025Review
- IRnet: Immunotherapy response prediction using pathway knowledge-informed graph neural network.Journal of advanced research · 2025Article
- Microbiota mechanisms in cancer progression and therapy.Cell chemical biology · 2025Review
- Article
- Discovering microbiota functions via chemical probe incorporation for targeted sequencing.Current opinion in chemical biology · 2025Review
- Gut microbiota in colorectal cancer: a review of its influence on tumor immune surveillance and therapeutic response.Frontiers in oncology · 2025Review
- Mechanisms by Which the Intratumoral Microbiome May Potentiate Immunotherapy Response.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Article
- Secreted antigen A peptidoglycan hydrolase is essential forbioRxiv : the preprint server for biology · 2024Article
- Microbial Influences on Immune Checkpoint Inhibitor Response in Melanoma: The Interplay between Skin and Gut Microbiota.International journal of molecular sciences · 2023Review
- Maestros of malignancy: Microbes as the conductors of carcinogenesis.Neoplasia (New York, N.Y.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The human microbiota acts as a diverse source of molecular cues that influence the development and homeostasis of the immune system. Beyond endogenous roles in the human holobiont, host-microbial interactions also alter outcomes for immune-related diseases and treatment regimens. Over the past decade, sequencing analyses of cancer patients have revealed correlations between microbiota composition and the efficacy of cancer immunotherapies such as checkpoint inhibitors. However, very little is known about the exact mechanisms that link specific microbiota with patient responses, limiting our ability to exploit these microbial agents for improved oncology care. Here, we summarize current progress towards a molecular understanding of host-microbial interactions in the context of checkpoint inhibitor immunotherapies. By highlighting the successes of a limited number of studies focused on identifying specific, causal molecules, we underscore how the exploration of specific microbial features such as proteins, enzymes, and metabolites may translate into precise and actionable therapies for personalized patient care in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.